more minor (Fig. S2, S3 , PERMANOVA based on infection status, acute stage, p=0.019, 139 R 2 =1.011% for positive mode LC-MS/MS analysis and p=0.07, R 2 =0.692% for negative mode 140 LC-MS/MS analysis; PERMANOVA based on infection status, chronic stage, p=0.014, 141 R 2 =0.982% for positive mode LC-MS/MS analysis and p=0.007, R 2 =0.981% for negative mode 142 LC-MS/MS analysis). Comparison of chemical families differentially-modulated by infection 143 also identified few commonalities between sample sites (Fig. S4, S5) . We therefore focused our 144 analysis on the impact of infection in each individual organ. Visualization of the chemical profile 145 in each organ in relationship to infection status using PCoA analysis revealed organ-specific 146 differences in the impact of T. cruzi infection. Acute-stage infection was associated with major 147 disturbances in the overall oesophagus chemical profile (PERMANOVA p=0.002, R 2 =15.871%), 148
with lower-scale perturbations in the small intestine and cecum (PERMANOVA p<0.001, 149 R 2 =6.95% and PERMANOVA p=0.02, R 2 =10.411%, respectively) ( Fig. 1e, S6) . The strongest 150 acute-stage disruption within the small intestine chemical environment was observed in the distal 151 small intestine, where parasite burden is the highest (Fig. 1e, PERMANOVA p<0 .001, 152 R 2 =30.198%; p<0.001, R 2 =26.063; p=0.006, R 2 =12.564, for positions 7, 8, 9, respectively) . 153
These changes resolved in the chronic stage for the cecum (PERMANOVA p=0.171, 154 R 2 =6.955%), decreased in magnitude for the small intestine ( PERMANOVA p<0.001, 155 R 2 =4.824), became apparent in the stomach and large intestine (PERMANOVA p=0.021, 156 R 2 =4.429% and PERMANOVA p=0.008, R 2 =6.323%, respectively), and increased in magnitude 157 in the oesophagus (PERMANOVA p<0.001, R 2 =38.061%). Importantly, the largest statistically 158 significant sites of metabolome disturbance in the chronic stage were the oesophagus and large 159 intestine, which are the sites of damage in symptomatic chronic-stage GI CD 14 . On a per-160 sampling site basis, spatial heterogeneity in terms of overall effect size (R 2 ) was observed within 161 a given organ. The largest increase in R 2 during the transition from the acute to the chronic stage 162 were observed in the oesophagus, distal stomach and central large intestine (2.4, 2.0 and 1.9-fold 163 increases, respectively). 164
Next, we investigated the nature of the chemical shifts associated with these infection-165 altered chemical profiles. Feature annotation rates were considerably higher in positive mode 166 than in negative mode (35.4% vs 10.2%), so we focused this analysis on our positive mode LC-167 MS/MS data. We used machine learning (random forest) approaches to identify specific 168 molecular features driving the differences between infected and uninfected tissues. Given our 169 observations on the impact of sampling position on metabolite features (PCoA, Fig. 1d, Fig. S2,  170   Fig. S3, Fig. S5 ), these comparisons were independently performed for each organ. In the acute 171 stage, we observed elevation in specific acylcarnitines and specific phosphatidylcholine (PC) 172 family members in the different organs ( Fig. 2a-f,Table S1, Fig. S7 ). We also observed 173 elevation in kynurenine in the stomach and large intestine in the acute stage. These differences 174 persisted in the chronic stage for the proximal and central large intestine only ( Fig. 2g-h , Table  175 S1, Fig. S7 ). Strikingly, the levels of tryptophan, the precursor of kynurenine, were 176 correspondingly decreased in the acute stage at the same large intestine sites where kynurenine 177 was elevated, whereas it was increased by infection in the chronic stage in the oesophagus (Fig.  178 2i-j). Kynurenine is induced by inflammation; kynurenine metabolites have direct antiparasitic 179 effects and contribute to the control of acute T. cruzi infection 15 . However, they can also induce 180 regulatory T cells 16 , and as such, our observation of kynurenine persistence in the large intestine 181 may contribute to parasite persistence in this organ. In accordance with our prior observations in 182 the context of the fecal metabolome 10 , specific large intestine and small intestine bile acid 183 derivatives were increased in infected mice ( Fig. 2k-m, Table S1, Fig. S7 ). At 89 days post-184 infection, molecular features identified as elevated by infection include specific acylcarnitines 185 (e.g. C20:4 acylcarnitine in the oesophagus), specific PCs (e.g. PC(22:5), PC(20:4), PC(22:6) in 186 the oesophagus; PC(22:4) in the large intestine), specific amino acids and derivatives (e.g. 187 kynurenine in the large intestine, tryptophan in the oesophagus) ( Fig. 2a-j, Table S1, Fig. S7 ). 188 Importantly, the pattern of persistence of these metabolic changes reflected known sites of CD: 189 for example, most of the top 10 metabolic perturbations observed in the acute stage in the 190 oesophagus were still perturbed by infection in the chronic stage, whereas none of the small 191 intestine acute-stage perturbations persisted in the chronic stage ( Fig. 2, Table S1 ). Overall, 192 these results identified tissue metabolic changes linked to CD tropism and pathogenesis, at the 193 scale of overall chemical disturbances, as well as several metabolic pathways correlated with 194 infection status. 195
Impact of T. cruzi colonization on the GI tract microbiome 197
Several of the molecules identified in our dataset are of microbial origin or microbially-198 modified, such as indole-L-lactate, indoxyl sulfate and secondary bile acids ( Fig. S8, Table S2 ). 199
Dataset match analysis through the GNPS platform 17 identified 1689 unique matches in our 200 positive mode dataset to pure bacterial culture datasets not shared with pure mammalian culture 201 datasets, known plastics-derived contaminants or blank files, suggesting a potential bacterial 202 origin. Studies comparing germ-free and colonized mice have also shown that the microbiota 203 influences a variety of the metabolites detected in our study, including tryptophan, tyrosine and 204 maltotriose 1819 . Tryptophan and tyrosine in particular were affected by infection (tryptophan: 205 decreased in the large intestine overall, Mann-Whitney p=6.793e-06 (acute stage) and 206 p=0.004313 (chronic stage); tyrosine: decreased in the large intestine overall, Mann-Whitney 207 p=0.01518 (acute stage), non-significant (chronic stage)). We have previously demonstrated that 208 experimental T. cruzi infection alters the fecal microbiome and metabolome 10 , a finding that was 209 recently confirmed in T. cruzi-infected children in Bolivia 20 . We therefore sought to evaluate the 210 spatial impact of T. cruzi infection on the microbiota at each collection site in acute-stage disease 211
(except for the oesophagus where insufficient material was available to perform both 212 metabolomic and 16S analyses), and focusing on the cecum and large intestine in chronic 213 disease, given their role as major sites of CD pathogenesis and the unique metabolomic pattern 214 observed at these sites ( Fig. 1e) . 215
Differences in the overall microbiota composition (beta-diversity, all sites combined for a 216 given organ) were observed in the stomach and large intestine in the acute stage (PERMANOVA 217 p=0.05, R 2 =3.22% and PERMANOVA p=0.04, R 2 =3.837%, respectively), with non-significant 218 changes in the small intestine and cecum (PERMANOVA p=0.069, R 2 =1.791% and 219 PERMANOVA p=0.058, R 2 =10.657%, respectively). These differences increased in magnitude 220 for the cecum and large intestine during the transition from acute to chronic stage 221 (PERMANOVA p=0.02, R 2 =11.556% and PERMANOVA p=0.002, R 2 =5.83%, respectively) 222 ( Fig. 3a-f ). Spatial heterogeneity was also observed within an organ ( Fig. 3g) , with the highest 223 disturbances in the microbiota found in the proximal large intestine (sampling position 11, 224 PERMANOVA p=0.022, R 2 =12.36% and PERMANOVA p=0.009, R 2 =10.715% for acute and 225 chronic stage, respectively). Persistent disturbances in the large intestine microbiota reflect our 226 findings for the large intestine metabolome, while the discrepancies between cecal microbiota 227 and metabolome findings may reflect persistent luminal rather than tissue alterations. Overall, 228 the persistence of microbiota alterations in these sites correlates well with our observation of 229 continued alterations of the fecal microbiota and metabolome through acute and chronic 230 experimental CD 10 . In accordance with prior reports 2010 , no significant differences in alpha-231 diversity were observed ( Fig. S9 ) between infected and uninfected tissue in both acute and 232 chronic stages. Notably, the effect size observed for microbiota composition analysis was lower 233 than for our tissue metabolomics analysis ( Fig. 1) , although in both cases the proximal large 234
intestine was one of the major sites of infection-associated perturbation. This may reflect 235 segregation of the microbiome from the site of infection, so that only indirect effects can be 236 observed. Furthermore, cage and batch effects were found to have a larger impact on microbiome 237 composition ( Fig. S10) , while metabolome analysis was more robust to such effects, as we 238 previously reported 10 . 239 240
Role of acylcarnitines in CD tolerance 241
Translating 'omics findings into novel therapeutic approaches is one of the major 242 challenges of this post-genome era. Because we observed larger metabolome than microbiome 243 infection-associated perturbations, and based on our current observations of infection-induced 244 elevation in specific acylcarnitine family members, and our prior findings of differential cardiac 245 acylcarnitine distribution and mass range in mild vs severe acute T. cruzi infection 13 , we focused 246 here on acylcarnitines and the potential of acylcarnitine modulation for CD treatment. The 247 acylcarnitine sub-network ( Fig. 4a ) was manually annotated ( Table S3 , Fig. S11a ), and impacts 248 of infection on short-chain (C3-C4), mid-chain (C5-C11) and long-chain (C12 and greater) 249 acylcarnitines assessed. While total and short-chain GI short-chain acylcarnitine levels were 250 comparable between infected and uninfected animals 12 days post-infection ( Fig. S11bc) , we 251 observed significant elevation in total and short-chain acylcarnitine levels at each small intestine 252 site, in infected animals (total acylcarnitines: FDR-corrected Mann-Whitney p=0.00543, 253 p=0.000422, p=7.04e-05, p=7.04e-05, p=0.000422 for positions 5, 6, 7, 8, 9; short-chain 254 acylcarnitines: FDR-corrected Mann-Whitney p=0.000668, p=0.000563, p=0.000141, 255 p=0.000563, p=0.00189 for positions 5, 6, 7, 8, 9; Fig . S11de ). For long-chain acylcarnitines, 256 infection-induced acylcarnitine elevation was restricted to the distal portions of the small 257 intestine (FDR-corrected Mann-Whitney p=0.000141, p=0.000563, p=0.000563 for positions 7, 258 8, 9; Fig. 4bc ). This difference between total and spatially-resolved short-chain acylcarnitine 259 levels highlight the strength of our chemical cartography approach. Mid-chain (C5 to C11) 260 acylcarnitine levels were not significantly different 12 days post-infection between infected and 261 uninfected animals at any GI site ( Fig. S11f) . Acylcarnitine small intestine elevation was no 262 longer observed in the chronic stage, except for short-chain acylcarnitines in the duodenum 263 (sampling position 5, FDR-corrected Mann-Whitney p=0.0253), although select other GI sites 264 showed infection-induced increases in acylcarnitines ( Fig. S11ghi ; distal large intestine, total 265 acylcarnitines and short-chain acylcarnitines, FDR-corrected Mann-Whitney p=0.0196 and 266 p=0.0387, respectively; oesophagus, short-chain acylcarnitines, FDR-corrected Mann-Whitney 267 p=0.00422). Acetyl-carnitine was also elevated in select sites 12 days post-infection (FDR-268 corrected Mann-Whitney p=0.0.0220, p=0.003413, p=0.000141, p=0.000141, p=0.0008913, 269 p=0.0220 for sites number 4-9 (stomach and small intestine, 12 days post-infection)), but was 270 comparable between infected and uninfected tissues at all sites 89 days post-infection ( Fig.  271 S11jk). In contrast, unmodified carnitine levels were comparable throughout the intestine 12 272 days post-infection, and only significantly elevated in infected oesophagus and uninfected central 273 large intestine 89 days post-infection (FDR-corrected Mann-Whitney p=0.000141 and p=0. 274 0187, respectively) ( Fig. S11l) . 275
To determine whether we could translate these findings towards novel CD therapeutics 276 and whether these acylcarnitine alterations play a causal role in disease progression, we assessed 277 whether carnitine supplementation could alter acute CD outcome. Mice were infected with either 278 an intermediate dose (5,000 trypomastigotes) or a high dose (50,000 trypomastigotes) of 279 luciferase-expressing CL Brener parasites 6 . At 7 days post-infection, animals were distributed 280 into two groups of comparable parasite burden and one group switched from normal drinking 281 water to drinking water supplemented with L-carnitine (equivalent to 100 mg/kg/day based on 282 water consumption). Carnitine treatment completely abrogated acute CD-induced mortality up to 283 7 weeks post-infection ( Fig. 4d, p=0 .0027 Mantel-Cox test, 50,000 trypomastigote infection; 284
Fig. S12a), but without any effect on parasite burden or parasite distribution ( Fig. 4ef, S12b) . 285
This lack of antiparasitic activity is consistent with prior in vitro activity data showing no impact 286 of carnitine on parasite burden 21 . Overall, these results indicate that acylcarnitine modulation by 287 carnitine supplementation can induce disease tolerance in CD. These results have important 288 implications for our understanding of the factors that contribute to the progression from 289 asymptomatic to symptomatic CD, and represent a novel avenue for CD drug development, in 290 conjunction with antiparasitics to kill T. cruzi. 291 292 Discussion:
293 Disease severity is tied to the balance between resistance and tolerance mechanisms 22 . 294
Resistance reduces pathogen load, but can cause collateral damage to the host, as indeed has 295 been observed with immune clearance of T. cruzi-infected cells 23 . In contrast, tolerance reduces 296 disease or immune-mediated collateral damage without affecting the pathogen load 22 . While 297 parasite persistence is required for progression to chronic CD 24 , only a minority of infected 298 patients progress to symptomatic disease 4 , and parasite load does not fully predict disease 299 severity (e.g. 25 ), indicating that disease tolerance mechanisms also regulate CD progression, 300 although these are not well understood. Our novel finding that carnitine modulation determines 301 infection outcome (Fig. 4) paves the way for future studies of the role of acylcarnitines in the 302 progression from asymptomatic to symptomatic disease in humans, as well as the development 303 of novel interventional strategies for CD, most likely in combination with antiparasitic agents. 304
Our observations also represent the first time that carnitine metabolism has been directly linked 305 to disease tolerance mechanisms, rather than serving as a readout for altered fatty acid 306 metabolism. Importantly, acylcarnitines, as with many other infection-modulated metabolites in 307 our dataset, showed strong spatial effects that would have been masked by bulk tissue analysis, 308 demonstrating the strength of this spatially-resolved approach (Fig. 2, Fig. 4b, Fig. S11 ). 309
Strikingly, sites of largest statistically significant overall metabolic disturbance in the chronic 310 stage were the oesophagus and large intestine ( Fig. 1) , providing a mechanism whereby 311 persistent metabolic alterations at these sites drive the striking selective tropism of CD for the 312 large intestine and oesophagus. In contrast, chronic parasite persistence in the cecum was 313 metabolically silent ( Fig. 1) , while cecal microbiome remained strongly and significantly 314 affected by infection ( Fig. 3) . It is tempting to speculate a microbiota-mediated mechanism of 315 reduced antiparasitic immune responses in the cecum, perhaps via cecal microbiota-derived 316 short-chain fatty acid 26 , or induction of parasite dormancy at this site 27 , leading to the observed 317 parasite recrudescence in the cecum following incomplete posaconazole or nifurtimox treatment 318 828 , and this awaits further experimentation. Lastly, the spatially-resolved metabolomic and 319 microbiome methods that we illustrate here with T. cruzi can readily be applied to study other 320 pathogens with specific tissue tropism, and we anticipate this approach to have broad 321 applicability. Likewise, initial pathogen tropism is affected by tissue characteristics. Our 322 comprehensive spatial characterization of the microbiome and metabolome of uninfected animals 323 therefore represents a resource that can serve as a hypothesis-generating starting point for studies 324 of pathogen tropism. analyzed jointly. Metabolites were extracted from the collected tissue samples using a two-step 365 process as implemented in our prior work 13 , normalizing to tissue weight. Tissue samples were 366 homogenized in LC-MS grade water (50 mg tissue in 125 µL water) using a 5 mm steel ball in 367
Qiagen TissueLyzer at 25 Hz for 3 min. 10 µL was set aside for DNA extraction and microbiome 368 profile analysis, except for oesophagus where the tissue amount was too small. LC-MS grade 369 methanol spiked with 4 µM sulfachloropyridazine was added to the homogenized sample, to a 370 final concentration of 50% methanol, and the sample was homogenized again at 25 Hz for 3 min. 371
Homogenate was centrifuged for 15 min at 14,980g, 4 ºC. The centrifugation supernatant was 372 collected and dried in a Savant SPD111V (ThermoFisher Scientific) speedvac concentrator. The 373 centrifugation pellet was resuspended in 3:1 (by volume) dichloromethane/methanol solvent 374 mixture and further homogenized at 25 Hz for 5 minutes, followed by centrifugation at 14,980g 375 for 2 minutes. This latter centrifugation supernatant was collected and air dried. Both extracts 376 were stored at -80 ºC until LC-MS analysis. Table S8 for parameters). Data was filtered to only retain MS1 scans that were present in at least 392 6 samples and were associated with MS2 spectra (and therefore could potentially be annotated). 393
Blank removal was performed, with a minimum three-fold difference between blank and samples 394 required in order for a feature to be retained. Total Ion Current (TIC) normalization was 395 performed in Jupyter notebook using R (http://jupyter.org). Principal coordinate analysis (PCoA) 396 was performed on the TIC-normalized MS1 data using the Bray-Curtis-Faith dissimilarity metric 397 in QIIME 1 32 , visualized using Emperor 33 . PERMANOVA calculations were performed on 398
Bray-Curtis-Faith distance matrices using the R package "vegan" 34 . The 3D GI tract model was 399 built to scale from pictures of GI tract samples collected from our mice, using SketchUp 2017 400 software. Data was plotted onto this 3D model using 'ili (https://ili.embl.de/) 35 . Feature 401 annotation was performed through molecular networking on the Global Natural Products Social 402
Networking (GNPS) platform 17 (see Table S9 for detailed parameters). All annotations are 403 levels 2 or 3 according to the metabolomics standards initiative 36 . Molecular networks were 404 visualized using Cytoscape 3738 . Venn diagrams were generated using: 405 http://bioinformatics.psb.ugent.be/webtools/Venn/. Random forest analysis 39 was performed in 406
Jupyter notebook using the randomForest R package and 7501 trees, classifying based on 407 infected vs uninfected status. All code can be accessed at https://github.com/mccall-lab-OU/GI-408 tract-paper. Nat. Rev. Mol. Cell Biol. 13, 263-269 (2012) . oesophagus (1) stomach (2) stomach (3) stomach (4) SI (5) SI (6) SI (7) SI (8) SI (9) cecum (10) LI (11) LI (12) LI (13) Sampling position analysis showing significant chemical composition differences between infected and uninfected 581 samples in oesophagus (acute stage, PERMANOVA p=0.002, R 2 =15.871%; chronic stage 582 PERMANOVA p<0.001, R 2 =38.061%), stomach (chronic stage, PERMANOVA p=0.021, 583 R 2 =4.429%; non-significant acute stage), small intestine, (acute stage, PERMANOVA p<0.001, 584 R 2 =6.95%; chronic stage, PERMANOVA p<0.001, R 2 =4.824), cecum (acute stage, PERMANOVA 585 p=0.02, R 2 =10.411%; non-significant chronic stage) and large intestine (chronic stage, PERMANOVA 586 p=0.008, R 2 =6.323%; non-significant acute stage). Bottom right-hand panels display R 2 at each 587 sampling site (common logarithmic scale, acute and chronic stage). 16S sequencing was performed on homogenate from all sampling sites except oesophagus in the 618 acute stage, and focusing on large intestine and cecum in the chronic stage. Principal coordinate 619 analysis revealed significant differences in the overall microbiota composition in the stomach (a) 620 and large intestine (d) in the acute stage (PERMANOVA p=0.05, R 2 =3.22% and PERMANOVA 621 p=0.04, R 2 =3.837%, respectively), which persisted in the chronic stage for the large intestine (f, 622 PERMANOVA p=0.002, R 2 =5.83%). Spatial heterogeneity was also observed within an organ 623 (g), with the highest disturbances in the microbiota in the proximal large intestine (sampling 624 position 11, PERMANOVA p=0.022, R 2 =12.36% and PERMANOVA p=0.009, R 2 =10.715% for 625 acute and chronic stage, respectively). (g) displays R 2 at each sampling site in the acute stage 626 
